BioCryst Pharmaceuticals Inc (BCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
BioCryst Pharmaceuticals Inc (BCRX) Earnings: Report Dates and Results
BioCryst Pharmaceuticals (BCRX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, BioCryst Pharmaceuticals reported EPS of $0.14, above the $0.10 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BCRX has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 92.9% below the $1.12 reported for the quarter ended Dec 31, 2025.
BCRX Earnings Call
The latest BCRX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, BCRX beat 18, missed 13 and matched 8. Revenue for the quarter ended Sep 30, 2026 was $180.29M, up 13.1% from $159.40M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.14 | $0.10 | $0.10 - $0.13 | +40.00% | Beat | -12.5% | 2 | 1 up, 1 down | Nov 4, 2026 | $180.29M |
| Jun 30, 2026 | $0.30 | $0.14 | $0.08 - $0.39 | +114.29% | Beat | +650.0% | 2 | 0 up, 1 down | Aug 5, 2026 | $218.25M |
| Mar 31, 2026 | $0.14 | $0.11 | $0.10 - $0.14 | +27.27% | Beat | +139900.0% | 4 | 1 up, 0 down | May 6, 2026 | $156.41M |
| Dec 31, 2025 | $1.12 | $0.07 | $0.04 - $0.12 | N/A | N/A | N/A | 3 | 1 up, 0 down | Feb 26, 2026 | $406.56M |
| Sep 30, 2025 | $0.16 | $0.07 | $0.02 - $0.15 | +128.57% | Beat | N/A | 4 | 1 up, 0 down | Nov 3, 2025 | $159.40M |
| Jun 30, 2025 | $0.04 | $0.03 | $0.00 - $0.10 | +33.33% | Beat | N/A | 6 | 1 up, 1 down | Aug 4, 2025 | $163.35M |
| Mar 31, 2025 | $0.00 | -$0.05 | -$0.08 - -$0.04 | +100.20% | Beat | N/A | 5 | 1 up, 2 down | May 5, 2025 | $145.53M |
| Dec 31, 2024 | -$0.13 | -$0.06 | -$0.10 - -$0.01 | -115.23% | Miss | N/A | 5 | 1 up, 2 down | Feb 24, 2025 | $131.53M |
| Sep 30, 2024 | -$0.07 | -$0.08 | -$0.09 - -$0.03 | +12.50% | Beat | N/A | 9 | 0 up, 0 down | Nov 4, 2024 | $117.08M |
| Jun 30, 2024 | -$0.06 | -$0.16 | -$0.32 - -$0.14 | +62.50% | Beat | N/A | 11 | 0 up, 0 down | Aug 5, 2024 | $109.33M |
| Mar 31, 2024 | -$0.17 | -$0.23 | -$0.28 - -$0.14 | +26.09% | Beat | N/A | 11 | 0 up, 0 down | May 6, 2024 | $92.76M |
| Dec 31, 2023 | -$0.28 | -$0.24 | -$0.38 - -$0.14 | -16.67% | Miss | N/A | 11 | 0 up, 0 down | Feb 26, 2024 | $93.40M |
| Sep 30, 2023 | -$0.19 | -$0.19 | -$0.41 - -$0.12 | 0.00% | In line | N/A | 10 | 0 up, 0 down | Nov 2, 2023 | $86.74M |
| Jun 30, 2023 | -$0.24 | -$0.21 | -$0.31 - -$0.14 | -14.29% | Miss | N/A | 10 | 1 up, 0 down | Aug 3, 2023 | $82.49M |
| Mar 31, 2023 | -$0.28 | -$0.29 | -$0.37 - -$0.16 | +3.45% | Beat | N/A | 11 | 1 up, 0 down | May 3, 2023 | $68.78M |
| Dec 31, 2022 | -$0.38 | -$0.17 | -$0.45 - $0.16 | -123.53% | Miss | N/A | 11 | 0 up, 3 down | Feb 21, 2023 | $79.55M |
| Sep 30, 2022 | -$0.23 | -$0.26 | -$0.46 - -$0.12 | +11.54% | Beat | N/A | 12 | 1 up, 3 down | Nov 1, 2022 | $75.83M |
| Jun 30, 2022 | -$0.32 | -$0.35 | -$0.48 - -$0.20 | +8.57% | Beat | N/A | 12 | 0 up, 0 down | Aug 4, 2022 | $65.53M |
| Mar 31, 2022 | -$0.40 | -$0.40 | -$0.52 - -$0.10 | 0.00% | In line | N/A | 13 | 1 up, 0 down | May 5, 2022 | $49.92M |
| Dec 31, 2021 | -$0.10 | -$0.30 | -$0.38 - -$0.21 | +66.67% | Beat | N/A | 13 | 0 up, 0 down | Feb 23, 2022 | $47.16M |
| Sep 30, 2021 | -$0.33 | -$0.29 | -$0.38 - -$0.19 | -13.79% | Miss | N/A | 12 | N/A | Nov 3, 2021 | $40.99M |
| Jun 30, 2021 | -$0.24 | -$0.25 | -$0.34 - -$0.16 | +4.00% | Beat | N/A | 11 | N/A | Aug 5, 2021 | $49.96M |
| Mar 31, 2021 | -$0.36 | -$0.27 | -$0.31 - -$0.22 | -33.33% | Miss | N/A | 11 | N/A | May 6, 2021 | $19.06M |
| Dec 31, 2020 | -$0.34 | -$0.25 | -$0.36 - -$0.15 | -36.00% | Miss | N/A | 10 | N/A | Feb 25, 2021 | $4.02M |
| Sep 30, 2020 | -$0.26 | -$0.26 | -$0.31 - -$0.17 | 0.00% | In line | N/A | 10 | N/A | Nov 5, 2020 | $6.10M |
| Jun 30, 2020 | -$0.24 | -$0.25 | -$0.30 - -$0.22 | +4.00% | Beat | N/A | 9 | N/A | Aug 6, 2020 | $2.87M |
| Mar 31, 2020 | -$0.24 | -$0.24 | -$0.31 - -$0.21 | 0.00% | In line | N/A | 9 | N/A | May 6, 2020 | $4.82M |
| Dec 31, 2019 | -$0.02 | -$0.27 | -$0.39 - -$0.05 | +92.59% | Beat | N/A | 9 | N/A | Mar 5, 2020 | $39.73M |
| Sep 30, 2019 | -$0.34 | -$0.31 | -$0.35 - -$0.27 | -9.68% | Miss | N/A | 9 | N/A | Nov 6, 2019 | $1.77M |
| Jun 30, 2019 | -$0.34 | -$0.32 | -$0.34 - -$0.25 | -6.25% | Miss | N/A | 9 | N/A | Aug 6, 2019 | $1.45M |
| Mar 31, 2019 | -$0.28 | -$0.28 | -$0.33 - -$0.22 | 0.00% | In line | N/A | 9 | N/A | May 8, 2019 | $5.89M |
| Dec 31, 2018 | -$0.25 | -$0.25 | -$0.32 - -$0.21 | 0.00% | In line | N/A | 9 | N/A | Mar 4, 2019 | $2.73M |
| Sep 30, 2018 | -$0.28 | -$0.26 | -$0.31 - -$0.14 | -7.69% | Miss | N/A | 8 | N/A | Nov 6, 2018 | $1.45M |
| Jun 30, 2018 | -$0.19 | -$0.24 | -$0.29 - -$0.21 | +20.83% | Beat | N/A | 8 | N/A | Aug 7, 2018 | $12.49M |
| Mar 31, 2018 | -$0.26 | -$0.19 | -$0.27 - -$0.14 | -36.84% | Miss | N/A | 8 | N/A | May 8, 2018 | $3.98M |
| Dec 31, 2017 | -$0.20 | -$0.15 | -$0.21 - -$0.09 | -33.33% | Miss | N/A | 9 | N/A | Feb 27, 2018 | $3.89M |
| Sep 30, 2017 | -$0.18 | -$0.18 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 7, 2017 | $8.76M |
| Jun 30, 2017 | -$0.21 | -$0.19 | N/A | -10.53% | Miss | N/A | N/A | N/A | Aug 7, 2017 | $3.10M |
| Mar 31, 2017 | -$0.19 | -$0.19 | N/A | 0.00% | In line | N/A | N/A | N/A | May 4, 2017 | $9.44M |
| Dec 31, 2016 | -$0.06 | -$0.23 | N/A | +73.91% | Beat | N/A | N/A | N/A | Feb 27, 2017 | $8.98M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.32, a profit after a loss of $0.43 per share the year before. It was -$0.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.32 | N/A |
| Dec 31, 2024 | -$0.43 | N/A |
| Dec 31, 2023 | -$0.99 | N/A |
| Dec 31, 2022 | -$1.33 | N/A |
| Dec 31, 2021 | -$1.03 | N/A |
| Dec 31, 2020 | -$1.08 | N/A |
| Dec 31, 2019 | -$0.98 | N/A |
| Dec 31, 2018 | -$0.98 | N/A |
| Dec 31, 2017 | -$0.78 | N/A |
| Dec 31, 2016 | -$0.75 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,350 | 15 | |
| 2026Q2 | Jun 30, 2026 | 5,016 | 14 | |
| 2026Q1 | Mar 31, 2026 | 4,690 | 14 | |
| 2025Q4 | Dec 31, 2025 | 5,835 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,618 | 15 | |
| 2025Q2 | Jun 30, 2025 | 6,680 | 16 | |
| 2025Q1 | Mar 31, 2025 | 8,704 | 15 | |
| 2024Q4 | Dec 31, 2024 | 9,066 | 15 |
2026Q3 Earnings Call
Opening remarks
Nick Wilder Company Representative Good morning, and welcome to BioCryst's Third Quarter 2026 Corporate Update and Financial Results Conference Call. Participating with me today are President and CEO Charles K. Gayer, Chief Financial Officer Babar Ghias, and Chief R&D Officer Dr. Sandeep Menon. A press release and slide presentation about today's news are available on our investor relations website. Today's call contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and achievements. These statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide 2 of the presentation. In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our investor relations website. I would now like to turn the call over to Charles.
Charles K. Gayer CEO Thanks, Nick. The third quarter was significant for BioCryst as we continue to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for ORLADEYO continued at the same high level that we have seen all year. We again added new prescribers at a rate above the average of the past several quarters, and the total base of treated patients grew at a healthy rate in the quarter. We were thrilled to launch ORLADEYO pellets for kids in August, and early signs of performance continue to be promising. Children of all ages across the 2-to-11 range have started on ORLADEYO pellets, and the mix of kids switching from other prophylaxis, those switching from acute-only treatment, and those who were treatment-naive has been balanced. This suggests the pediatric market may grow beyond the 500 patients that we have previously described. We are also looking forward to launching the recently approved 150-milligram ORLADEYO pellets at the upcoming American College of Allergy, Asthma, and Immunology meeting this month. This new formulation for ages 12 and up provides an option for kids who started on pellets, for adolescents and adults who have difficulty swallowing a capsule, or for anyone who simply prefers the pellet formulation. We are looking forward to generating real-world evidence to track the progress and patterns of use for all patients treated with ORLADEYO pellets. During the third quarter, we also implemented the transition to CareMed as our sole-source pharmacy partner for shipments to patients.
Frequently Asked Questions About BCRX
When is BioCryst Pharmaceuticals's next earnings date?
BioCryst Pharmaceuticals's next earnings report is expected for Feb 24, 2027.
Did BCRX beat earnings estimates last quarter?
Yes. BioCryst Pharmaceuticals reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.10 estimate, a 40.00% surprise.
What EPS do analysts expect from BCRX next quarter?
The consensus EPS estimate for BioCryst Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.08 from 12 analysts, with estimates from $0.02 to $0.17.
How often does BCRX beat earnings estimates?
BioCryst Pharmaceuticals beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +42.62%.
BCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts